To co-market Cospiaq, Cospiaq Met and Xilingio in India
Torrent Pharmaceuticals has entered into a strategic alliance with Boehringer Ingelheim India (BI India) to co-market Cospiaq (Empagliflozin), Cospiaq Met& trade; (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin) in India.Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. Further, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
